UK judge notes 'confidential impediment' in Nirav Modi extradition case
Nirav Modi's bail plea was rejected by a London High Court judge, citing a 'confidential impediment' hindering his extradition to India. Despite arguments about the delay and his health, the judge deemed the risk of Modi absconding too high. The confidential proceedings, possibly related to an asylum application, remain a key factor in the ongoing legal battle.
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
A London High Court judge who refused Nirav Modi's latest bail application this week has taken note in his judgment of a " confidential impediment " in the long-drawn extradition proceedings against the imprisoned diamantaire wanted in India on fraud and money laundering charges Justice Michael Fordham on Thursday concluded at a Royal Courts of Justice bail hearing that there are substantial grounds for believing that if released on bail, the 54-year-old businessman would "fail to surrender" and his risk of absconding remained high.While Nirav's barrister argued in favour of his bail from London's Thameside prison based on the "long passage of time" without trial, the judge highlighted the constraints of a "confidential" process that prevented his surrender to the Indian authorities even though the legal process related to his extradition had "run its course"."There is a 'legal reason' which relates to 'confidential proceedings'. The nature of this is known to the applicant (Nirav Modi), and his lawyers; it is known to the Home Office, but apart from what I have recorded, nothing is known by the CPS [Crown Prosecution Service] or by the Government of India, nor by this court," Justice Fordham states.CPS barrister Nicholas Hearn, appearing on behalf of the Indian authorities, confirmed to the court that he "recognises and respects" the fact of the "existing confidential impediment" and the fact of its confidentiality, for "whatever reason it is being kept confidential"."It is appropriate, in the circumstances, that the court should proceed with the same recognition and respect. But the consequence is this: there is, as a result, a significant limitation to what this court can realistically assess, when considering the risks and implications in this case, and for that matter when considering how to characterise the now long passage of time," the judge concluded in his ruling.The confidential proceedings, alluded to at various previous court hearings linked with Nirav Modi, are believed to refer to an asylum application , but the exact nature of the matter is unclear.Meanwhile, Nirav has remained in prison in London since his arrest in March 2019 and has made at least seven previous bail attempts, which have all been rejected because he poses a flight risk.Justice Fordham said he considered the legal appropriateness for him to consider the latest bail application "afresh" and with a "clean slate"."I have had close regard to the points which have been made about the human cost of detention. That includes all of the points that have been advanced about physical and mental health, including in terms of deterioration and delays in treatment, and the concerns very properly raised in the clinicians' expert evidence," Justice Fordham's judgment said."I have also taken account of the evidence about assaults and threats and the prospect of coercion... But I am not able to conclude that, when put alongside the other relevant features of the case, they can serve to displace or undermine the assessment which I have described (against bail)," it said.There are three sets of criminal proceedings against Nirav Modi in India - the Central Bureau of Investigation (CBI) case of fraud in the Punjab National Bank (PNB), the Enforcement Directorate (ED) case relating to the alleged laundering of the proceeds of that fraud, and a third set of criminal proceedings involving alleged interference with evidence and witnesses in the CBI proceedings.In April 2021, then UK home secretary, Priti Patel, ordered his extradition to face these charges in the Indian courts after a prima facie case was established against him.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
30 minutes ago
- First Post
Op Sindoor: Pakistan's Jacobabad airbase hangar that India hit covered with tarpaulin, show satellite images
'Recent imagery from Jacobabad Airbase, Pakistan indicates that the hangar damaged in the Indian airstrike is now covered with tarpaulin/ some other covering possibly signaling repair activity/restoration is now underway,' wrote Symon on X read more The images, shared by analyst Damien Symon on X, show possible repair or restoration efforts at the site. Recent satellite imagery from Pakistan's Jacobabad Airbase shows that the hangar reportedly damaged in the Indian airstrike is now covered with tarpaulin. The images, shared by analyst Damien Symon on X, show possible repair or restoration efforts at the site, which was among the targets hit during India's cross-border 'Operation Sindoor' last month. 'Recent imagery from Jacobabad Airbase, Pakistan indicates that the hangar damaged in the Indian airstrike is now covered with tarpaulin/ some other covering possibly signaling repair activity/restoration is now underway,' wrote Symon on X along with the satellite image. STORY CONTINUES BELOW THIS AD Recent imagery from Jacobabad Airbase, Pakistan indicates that the hangar damaged in the Indian airstrike is now covered with tarpaulin/ some other covering possibly signaling repair activity/restoration is now underway — Damien Symon (@detresfa_) June 6, 2025 Earlier, Symon released satellite images of Pakistan's Nur Khan and Murid airbases, showing visible infrastructure damage following Indian strikes. The attacks were reportedly in retaliation for Pakistani attempts to target Indian military installations. Imagery from the Murid Airbase revealed structural damage to a command-and-control facility, including a partially collapsed roof. In contrast, visuals from the Nur Khan Airbase showed a complex that appears to have been completely destroyed. With inputs from agencies
NDTV
31 minutes ago
- NDTV
'Rajnath Aam': Newly Developed Mango Variety Named After Defence Minister Rajnath Singh
Lucknow: Kalimullah Khan, popularly known as the 'Mango Man' of India, has named a newly developed mango variety after Defence Minister Rajnath Singh. Grown using his signature grafting technique in his Malihabad orchard, the new variety has been named 'Rajnath Aam'. Mr Khan, who has earlier named mango varieties after several prominent Indian personalities, including Sachin Tendulkar, Aishwarya Rai, Akhilesh Yadav, Sonia Gandhi, Narendra Modi, and Amit Shah, was awarded the Padma Shri for his unique contributions and dedication to horticulture and fruit breeding. Speaking about his latest tribute, Mr Khan told PTI Videos, "I name my mangoes after people who have served the country meaningfully. I want these names to live on for generations. "Sometimes people forget great leaders, but if a mango reminds them of Rajnath Singh's good work, then it's worth it. He is a balanced and thoughtful individual. During a recent discussion about Pakistan, I found that he sincerely desires peace, not war." On the Pahalgam terror attack in Kashmir that left 26 people dead, Mr Khan blamed Pakistan for initiating aggression. "But today, the atmosphere has improved. Peace, not conflict, is the solution. Problems should be resolved through dialogue. War only escalates hatred and brings harm to all. We are all human, and division only causes more damage," he said. Talking about the Malihabad region in Lucknow, known world over for its mangoes, Mr Khan recalled that there were more than 1,300 mango varieties in the area in 1919, but over time, many have disappeared from the market. "I've been working to preserve and revive them, and today I've developed over 300 varieties," he said. Mr Khan, who began experimenting with crossbreeding mangoes as a child, shared that he only studied up to Class 7. "I was never inclined toward classroom studies. I respected my teachers and classmates, but I kept failing in Classes 4, 5, 6, and even 7. My heart was always in the orchard." Born in 1945, according to official records, Mr Khan said he still feels physically fit, despite having undergone a heart surgery and facing other health issues in his 80s. Among his many creations, he spoke proudly of the "Asl-ul-Muqarrar" variety of mangoes, which he began developing in 1987. He also recalled an encounter with the then-World Bank president, who visited Malihabad. "I told him about a special mango tree that emitted a fragrant aroma, which I believe works like a tonic for the brain. At first, I wondered what I was doing, telling such things to such a high-ranking man. But he came to the orchard, smelled the tree's fragrance, and was amazed. He then instructed officials to allot me five acres of land to expand this work," he said. However, Mr Khan noted with a tinge of disappointment that despite the presence of senior officials from the central and state governments during that visit, no action was ever taken on the land promise. Speaking about his life's mission, Mr Khan said, "I want people to keep enjoying different varieties of mangoes long after I'm gone, especially those who truly love this fruit. Mango is one of the few fruits in the world that can help people stay healthy and has healing powers." He added that he has documented evidence of the mango's medicinal benefits in various places. "Now, we have to see how far the research institutions can take these findings and turn them into real scientific progress." (Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
&w=3840&q=100)
Business Standard
35 minutes ago
- Business Standard
Indian pharma market grows 7.2% in May led by chronic therapies
Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches Sanket Koul New Delhi The Indian Pharma Market (IPM) grew 7.2 per cent in May this year with almost all major therapies showing positive growth, according to market research firm Pharmarack. Data suggest that big chronic therapies such as cardiac and anti-infectives, which account for nearly 25 per cent of the overall domestic market, recorded value growth of 11.7 per cent and 7.6 per cent, respectively. On the other hand, several smaller supergroups such as urology and antineoplastics, which made up 2 per cent each of the IPM's sales value for the month, also recorded double-digit growth in May at 12.3 per cent and 11.7 per cent, said Sheetal Sapale, vice-president, commercial, Pharmarack. Data suggest that the overall value growth for the IPM in May was driven by price growth and new introductions. The IPM also reported a minuscule 0.4 per cent unit growth during the month, with the chronic segments such as antidiabetics (6.1 per cent) and cardiac (4.8 per cent) performing better than the overall market figure. Experts believe that the antidiabetic segment saw a 6.1 per cent rise in volume in May due to a key drug, empagliflozin, going off-patent, as companies launched several plain and combination medications in the segment. Growth in the moving annual turnover (MAT) for the IPM between June 2024 and May 2025 stood at 8.1 per cent, leading to a total turnover of over Rs 2.29 trillion, while volumes in the domestic market grew by 1.1 per cent. The MAT of leading therapy areas such as cardiac, gastrointestinal and anti-infectives, which constitute around 38 per cent of the pharmaceutical market, showed robust volume growth at 10.4 per cent, 9.5 per cent and 6.5 per cent, respectively. While the top 20 brands in the IPM registered modest monthly value growth in the domestic market during the month, Sun Pharma and Dr Reddy's posted significant monthly value growth at 11.2 per cent each. They were followed by Torrent Pharma and Ipca Laboratories at 10.8 per cent, and Alkem Laboratories at 10.3 per cent monthly value growth. According to Pharmarack data, GlaxoSmithKline's (GSK) antibiotic medication Augmentin and USV's anti-diabetic drug Glycomet GP continued to be the top-selling medicine brands at the MAT level, with sales worth Rs 819 crore and Rs 810 crore, respectively.
